$ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Healthcare
Sector
Biotechnology
Industry
Todd Franklin Watanabe
CEO
342
Employees
$23.63
Current Price
$3.27B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 2 weeks | Buys | 0 | 0 | - | - | - |
| Sells | 0 | 0 | - | - | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 1 | $238,801.00 | 10,000 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 7 | 15 | $3,069,928.57 | 121,506 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 7 | 25 | $5,285,849.09 | 208,818 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Feb 4, 2026 | Burnett Patrick Reporting Person's Title: Executive Vice President and Chief Medical Officer | Sale | 9,794 | $25.81 | $252,747.88 | View Details |
| Feb 2, 2026 | Watanabe Todd Director | Sale | 19,833 | $25.50 | $505,709.77 | View Details |
| Feb 2, 2026 | Vairavan Latha SVP Chief Financial Officer | Sale | 1,320 | $25.50 | $33,657.89 | View Details |
| Feb 2, 2026 | Welgus Howard G. Director | Sale | 10,000 | $25.05 | $250,483.00 | View Details |
| Feb 2, 2026 | Edwards Larry Todd Reporting Person's title: EVP Chief Commercial Officer | Sale | 2,052 | $25.50 | $52,322.72 | View Details |
67 more transactions available โ create a free account to see 12 months of history | ||||||
Showing 21โ25 of 25 transactions
Upcoming Earnings
Scheduled earnings reports
No upcoming earnings scheduled
Past Earnings
Historical earnings results
EPS
Estimated$0.03
ActualN/A
Revenue
Estimated$113.03M
ActualN/A
EPS
Estimated$0.02
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies: